Following a recent decision from the U.S. Court of Appeals for the Ninth Circuit in Khoja v. Orexigen Therapeutics, Inc., plaintiffs alleging securities fraud against companies in the pharmaceutical and life sciences sector...more
6/18/2019
/ Adverse Events ,
Defense Strategies ,
Extrinsic Evidence ,
Food and Drug Administration (FDA) ,
Life Sciences ,
Litigation Strategies ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Pre-Trial Motions ,
Prescription Drugs ,
Securities Fraud ,
Securities Litigation ,
Stock Drop Litigation